$24 AntennaMastsRus - Made in USA - 50 Caliber Bullet Aluminum Anten Electronics Car Vehicle Electronics Vehicle Electronics Accessories AntennaMastsRus - Made in USA Aluminum Anten 50 Bullet Caliber Oakland Mall in,USA,$24,pti-ny.com,50,Electronics , Car Vehicle Electronics , Vehicle Electronics Accessories,Bullet,Made,AntennaMastsRus,-,Aluminum,-,Caliber,Anten,/carpetbaggery1989475.html AntennaMastsRus - Made in USA Aluminum Anten 50 Bullet Caliber Oakland Mall in,USA,$24,pti-ny.com,50,Electronics , Car Vehicle Electronics , Vehicle Electronics Accessories,Bullet,Made,AntennaMastsRus,-,Aluminum,-,Caliber,Anten,/carpetbaggery1989475.html $24 AntennaMastsRus - Made in USA - 50 Caliber Bullet Aluminum Anten Electronics Car Vehicle Electronics Vehicle Electronics Accessories

AntennaMastsRus - Made in USA Aluminum shipfree Anten 50 Bullet Caliber Oakland Mall

AntennaMastsRus - Made in USA - 50 Caliber Bullet Aluminum Anten

$24

AntennaMastsRus - Made in USA - 50 Caliber Bullet Aluminum Anten

|||

Product description

Size:50 Cal Bullet

Your MAST Broken, Deteriorating, Stolen or Bent? Looking for an antenna to get rid of that obnoxiously tall un-stylish antenna your vehicle comes with? Looking for the BEST reception Short antenna on the market? Then look no further, this is the antenna solution for you!!

** This antennas main design is for appearance enhancements. Its AM/FM radio reception performance works best for local stations (Satellite Radio/Navigation/Bluetooth not effected). For the BEST reception short antenna check out our SHORT 6 3/4" antenna found in our store. Any questions or concerns on any of our products feel free to contact us by telephone or email by clicking on TheAntennaSource about us page here on Amazon.

AntennaMastsRus - Made in USA - 50 Caliber Bullet Aluminum Anten

CURRENT ISSUE
November, 2021

No. 106 (11)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Transducin β-like protein 1 (TBL1) plays a crucial role in controlling the stability of regulatory proteins involved in cell proliferation and autophagy induction. This study revealed that, unlike normal B cells, diffuse large B-cell lymphoma cells express abundant levels of TBL1 and its overexpression correlates with poor clinical outcome. Targeting TBL1 promoted lymphoma cell death in vitro and in vivo. These results provide the rationale for targeting TBL1 as a novel therapeutic strategy in diffuse large B-cell lymphoma.

Youssef Youssef et al.

Article

Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro

The authors of this study developed a single-chain antibody that targets a shear gradient-specific conformation of von Willebrnad factor (VWF). In vitro studies showed that this antibody specifically reduces VWF-GPIbα binding and thrombus formation at sites of shear rate gradients but does not block platelet deposition and aggregation under constant shear rate. This characteristic places the antibody in a new class of antiplatelet therapy for selective blockade of pathological thrombus formation while maintaining normal hemostasis.

Thomas Hoefer et al.

Case Report

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

A 26-year-old female developed vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis and bi-hemispheric hemorrhage following the first dose of the ChAdOx1 nCoV-19 vaccine. The treatment protocol, based on intravenous immunoglobulins, dexamethasone and argatroban was successful with almost complete clinical, laboratory and radiological response. This experience supports the application of an early and multidisciplinary therapeutic approach in cases of VITT, with the possibility of avoiding deaths and obtain a resolution of the syndrome.

Sara Bonato et al.

Letter

Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience

This retrospective study compared the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in 23 patients with hematologic malignancies transplanted from non-sibling fully matched related donors to that of patients who underwent conventional haplo-HSCT. Subjects transplanted from fully matched related donors showed trends to a higher relapse rate and lower cumulative incidence of grade II-IV acute graft-versus-host disease, but overall survival was similar. The authors concluded that individualized adjustment of the immunosuppressive treatment is reasonable for this category of patients.

Yaoyao Shen et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA